Vitamin D deficiency in HIV infection: Not only a bone disorder

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Mansueto, Pasquale ^a   Seidita, Aurelio ^a   Vitale, Giustina ^a   Gangemi, Sebastiano ^b,c   Iaria, Chiara ^d   Cascio, Antonio ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c CNR   (Italy)

^d Papardo Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS (TOPIC); NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TUBERCULOSIS; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; BONE DISEASES; COMPLICATION; HIV INFECTIONS; PREVALENCE; RISK FACTOR;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DISEASES; HIV INFECTIONS; HUMANS; PREVALENCE; RISK FACTORS; VITAMIN D DEFICIENCY;

EID: 84929352880     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/735615     Document Type: Review

References (99)

1. F. J. Palella Jr., R. K. Baker, A. C. Moorman et al., "Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study", Journal of Acquired Immune Defficiency Syndromes, vol. 43, no. 1, pp. 27-34, 2006.
2. G. Maartens, C. Celum, and S. R. Lewin, "HIV infection: epidemiology, pathogenesis, treatment, and prevention", The Lancet, vol. 384, no. 9939, pp. 258-271, 2014.
3. T. A. Rasmussen, M. Tolstrup, C. R. Brinkmann et al., "Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial", The Lancet, vol. 1, no. 1, pp. e13-e21, 2014.
4. S. G. Deeks, S. R. Lewin, and D. V. Havlir, "The end of AIDS: HIV infection as a chronic disease", The Lancet, vol. 382, no. 9903, pp. 1525-1533, 2013.
5. J. E. Lake and J. S. Currier, "Metabolic disease in HIV infection", The Lancet Infectious Diseases, vol. 13, no. 11, pp. 964-975, 2013.
6. V. A. Triant, "Cardiovascular disease and HIV infection", Current HIV/AIDS Reports, vol. 10, no. 3, pp. 199-206, 2013.
7. V. Appay and D. Sauce, "Immune activation and infammation in HIV-1 infection: causes and consequences", The Journal of Pathology, vol. 214, no. 2, pp. 231-241, 2008.
8. J. A. Aberg, "Aging, infammation, and HIV infection", Topics in Antiviral Medicine, vol. 20, no. 3, pp. 101-105, 2012.
9. D. E. Nixon and A. L. Landay, "Biomarkers of immune dysfunction in HIV", Current Opinion in HIV and AIDS, vol. 5, no. 6, pp. 498-503, 2010.
10. N. T. Funderburg, "Markers of coagulation and infammation ofen remain elevated in ART-treated HIV-infected patients", Current Opinion in HIV and AIDS, vol. 9, no. 1, pp. 80-86, 2014.
11. National Center for Health Statistics, Centers for Disease Control and Prevention, National health and nutrition examination survey, 2014, http://www.cdc.gov/nchs/nhanes/about nhanes.htm.
12. A. R. Eckard, T. Leong, A. Avery et al., "Short communication: high prevalence of vitamin D defficiency in HIV-infected and HIV-uninfected pregnant women", AIDS Research and Human Retroviruses, vol. 29, no. 9, pp. 1224-1228, 2013.
13. S. Mehta, E. Giovannucci, F. M. Mugusi et al., "Vitamin D status of HIV-infected women and its association with hiv disease progression, anemia, and mortality", PLoS ONE, vol. 5, no. 1, Article ID e8770, 2010.
14. D. H. Watts, "Treating HIV during pregnancy: an update on safety issues", Drug Safety, vol. 29, no. 6, pp. 467-490, 2006.
15. M. Aziz, B. Livak, J. Burke-Miller et al., "Vitamin D insuficiency may impair CD4 recovery among Women's Interagency HIV Study participants with advanced disease on HAART", AIDS, vol. 27, no. 4, pp. 573-578, 2013.
16. A. C. Ross, S. Judd, M. Kumari et al., "Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals", Antiviral Terapy, vol. 16, no. 4, pp. 555-563, 2011.
17. P. Wasserman and D. S. Rubin, "Highly prevalent vitamin D defficiency and insuficiency in an urban cohort of HIV-infected men under care", AIDS Patient Care and STDs, vol. 24, no. 4, pp. 223-227, 2010.
18. K. Gedela, S. G. Edwards, P. Benn, and A. D. Grant, "Prevalence of vitamin D defficiency in HIV-positive, antiretroviral treatment-näive patients in a single centre study", International Journal of STD & AIDS, vol. 25, no. 7, pp. 488-492, 2014.
19. S. M. Arpadi, D. McMahon, E. J. Abrams et al., "Efect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents", Pediatrics, vol. 123, no. 1, pp. e121-e126, 2009.
20. S. Kakalia, E. B. Sochett, D. Stephens, E. Assor, S. E. Read, and A. Bitnun, "Vitamin D supplementation and CD4 count in children infected with human immunodefficiency virus", The Journal of Pediatrics, vol. 159, no. 6, pp. 951-957, 2011.
21. J.-P. Viard, J.-C. Souberbielle, O. Kirk et al., "Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study", AIDS, vol. 25, no. 10, pp. 1305-1315, 2011.
22. V. L. Vecchi, M. Soresi, L. Giannitrapani et al., "Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected mediterranean subjects", BMC Infectious Diseases, vol. 12, article 192, 2012.
23. C. N. Dao, P. Patel, E. T. Overton et al., "Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the us general population", Clinical Infectious Diseases, vol. 52, no. 3, pp. 396-405, 2011.
24. F. Havers, L. Smeaton, N. Gupte et al., "5-hydroxyvitamin D insuficiency and defficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings", The Journal of Infectious Diseases, vol. 210, no. 2, pp. 244-253, 2014.
25. A. A. Lambert, M. B. Drummond, S. H. Mehta et al., "Risk factors for vitamin D defficiency among hiv-infected and uninfected injection drug users", PLoS ONE, vol. 9, no. 4, Article ID e95802, 2014.
26. C. E. Cherubin and J. D. Sapira, "The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later", Annals of Internal Medicine, vol. 119, no. 10, pp. 1017-1028, 1993.
27. L. S. Kahn, N. Satchidanand, A. Kopparapu, W. Goh, S. Yale, and C. H. Fox, "High prevalence of undetected vitamin D defficiency in an urban minority primary care practice", Journal of the National Medical Association, vol. 103, no. 5, pp. 407-411, 2011.
28. M. Guidi, G. Foletti, P. McLaren et al., "Vitamin D time profle based on the contribution of non-genetic and genetic factors in HIV-infected individuals of European ancestry", Antiviral Terapy, 2014.
29. M. Teodorou, T. Sersté, M. Van Gossum, and S. Dewit, "Factors associated with vitamin D defficiency in a population of 2044 HIV-infected patients", Clinical Nutrition, vol. 33, no. 2, pp. 274-279, 2014.
30. D. A. Wohl, C. Orkin, M. Doroana et al., "Change in vitamin D levels and risk of severe vitamin D defficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO)", Antiviral Terapy, vol. 19, no. 2, pp. 191-200, 2014.
31. N. Hariparsad, S. C. Nallani, R. S. Sane, D. J. Buckley, A. R. Buckley, and P. B. Desai, "Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital", Journal of Clinical Pharmacology, vol. 44, no. 11, pp. 1273-1281, 2004.
32. T. T. Brown and G. A. McComsey, "Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D", Antiviral Terapy, vol. 15, no. 3, pp. 425-429, 2010.
33. M. Ellfolk, M. Norlin, K. Gyllensten, and K. Wikvall, "Regulation of human vitamin D3 25-hydroxylases in dermal fbroblasts and prostate cancer LNCaP cells", Molecular Pharmacology, vol. 75, no. 6, pp. 1392-1399, 2009.
34. S. A. Bozzette, C. F. Ake, H. K. Tam, S. W. Chang, and T. A. Louis, "Cardiovascular and cerebrovascular events in patients treated for human immunodefficiency virus infection", The New England Journal of Medicine, vol. 348, no. 8, pp. 702-710, 2003.
35. N. Friis-Møller, P. Reiss, C. A. Sabin et al., "Class of antiretroviral drugs and the risk of myocardial infarction", The New England Journal of Medicine, vol. 356, no. 17, pp. 1723-1735, 2007.
36. C. Grunfield, J. A. Delaney, C. Wanke et al., "Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study", AIDS, vol. 23, no. 14, pp. 1841-1849, 2009.
37. P. Y. Hsue, P. W. Hunt, A. Schnell et al., "Role of viral replication, antiretroviral therapy, and immunodefficiency in HIV-associated atherosclerosis", AIDS, vol. 23, no. 9, pp. 1059-1067, 2009.
38. S. M. Crowe, C. L. V. Westhorpe, N. Mukhamedova, A. Jaworowski, D. Sviridov, and M. Bukrinsky, "The macrophage: the intersection between HIV infection and atherosclerosis", Journal of Leukocyte Biology, vol. 87, no. 4, pp. 589-598, 2010.
39. N. Friis-Moller, R. Weber, P. Reiss, R. Tiebaut, O. Kirk, and A. D'Arminio Monforte, "Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study", AIDS, vol. 17, no. 8, pp. 1179-1193, 2003.
40. M. Galli, A. L. Ridolfo, F. Adorni et al., "Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors", Journal of Acquired Immune Defficiency Syndromes, vol. 29, no. 1, pp. 21-31, 2002.
41. J. L. Anderson, H. T. May, B. D. Horne et al., "Relation of vitamin D defficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population", The American Journal of Cardiology, vol. 106, no. 7, pp. 963-968, 2010.
42. A. G. Pittas, M. Chung, T. Trikalinos et al., "Systematic review: vitamin D and cardiometabolic outcomes", Annals of Internal Medicine, vol. 152, no. 5, pp. 307-314, 2010.
43. D. Santoro, G. Gagliostro, A. Alibrandi et al., "Vitamin D receptor gene polymorphism and lef ventricular hypertrophy in chronic kidney disease", Nutrients, vol. 6, no. 3, pp. 1029-1037, 2014.
44. A. Vaidya and J. S. Williams, "The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes", Metabolism: Clinical and Experimental, vol. 61, no. 4, pp. 450-458, 2012.
45. A. I. Choi, J. C. Lo, K. Mulligan et al., "Association of vitamin D insuficiency with carotid intima-media thickness in HIV-infected persons", Clinical Infectious Diseases, vol. 52, no. 7, pp. 941-944, 2011.
46. J. Portilla, O. Moreno-Perez, C. Serna-Candel et al., "Vitamin D insuficiency and subclinical atherosclerosis in non-diabetic males living with HIV", Journal of the International AIDS Society, vol. 17, no. 1, Article ID 18945, 2014.
47. H. Lai, E. K. Fishman, G. Gerstenblith et al., "Vitamin D deficiency is associated with development of subclinical coronary artery disease in HIV-infected African American cocaine users with low Framingham-defned cardiovascular risk", Vascular Health and Risk Management, vol. 9, no. 1, pp. 729-737, 2013.
48. P. Tebas, "Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options", Journal of Acquired Immune Defficiency Syndromes, vol. 49, supplement 2, pp. S86-S92, 2008.
49. H. Khan, S. Kunutsor, O. H. Franco, and R. Chowdhury, "Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies", The Proceedings of the Nutrition Society, vol. 72, no. 1, pp. 89-97, 2013.
50. Z. Szep, G. Guaraldi, S. S. Shah et al., "Vitamin D defficiency is associated with type 2 diabetes mellitus in HIV infection", AIDS, vol. 25, no. 4, pp. 525-529, 2011.
51. O. M. Adeyemi, B. Livak, J. Orsi et al., "Vitamin D and insulin resistance in non-diabetic women's interagency HIV study participants", AIDS Patient Care and STDs, vol. 27, no. 6, pp. 320-325, 2013.
52. C. J. P. Van Den Bout-Van Den Beukel, M. Van Den Bos, W. J. G. Oyen et al., "The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-defficient HIV-1-infected patients", HIV Medicine, vol. 9, no. 9, pp. 771-779, 2008.
53. R. I. Connor and W. F. C. Rigby, "1α, 25-Dihydroxyvitamin D3 inhibits productive infection of human monocytes by HIV-1", Biochemical and Biophysical Research Communications, vol. 176, no. 2, pp. 852-859, 1991.
54. H. Schuitemaker, N. A. Kootstra, M. H. G. M. Koppelman et al., "Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages", The Journal of Clinical Investigation, vol. 89, no. 4, pp. 1154-1160, 1992.
55. C. Haug, F. Müller, P. Aukrust, and S. S. Fræland, "Subnormal serum concentration of 1, 25-vitamin D in human immunodefficiency virus infection: correlation with degree of immune defficiency and survival", The Journal of Infectious Diseases, vol. 169, no. 4, pp. 889-893, 1994.
56. J. Teichmann, E. Stephan, T. Discher et al., "Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodefficiency virus infection", Metabolism: Clinical and Experimental, vol. 49, no. 9, pp. 1134-1139, 2000.
57. S. Mehta, F. M. Mugusi, D. Spiegelman et al., "Vitamin D status and its association with morbidity including wasting and opportunistic illnesses in HIV-infected women in Tanzania", AIDS Patient Care and STDs, vol. 25, no. 10, pp. 579-585, 2011.
58. J. E. Sherwood, O. C. Mesner, A. C. Weintrob et al., "Vitamin D defficiency and its association with low bone mineral density, HIV-related factors, hospitalization, and death in a predominantly black HIV-infected cohort", Clinical Infectious Diseases, vol. 55, no. 12, pp. 1727-1736, 2012.
59. G. L. Armstrong, A. Wasley, E. P. Simard, G. M. McQuillan, W. L. Kuhnert, and M. J. Alter, "The prevalence of hepatitis C virus infection in the United States, 1999 through 2002", Annals of Internal Medicine, vol. 144, no. 10, pp. 705-714, 2006.
60. F. J. Torriani, M. Rodriguez-Torres, J. K. Rockstroh et al., "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients", The New England Journal of Medicine, vol. 351, no. 5, pp. 438-450, 2004.
61. H.-H. Tein, Q. Yi, G. J. Dore, and M. D. Krahn, "Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis", AIDS, vol. 22, no. 15, pp. 1979-1991, 2008.
62. M. W. Hull, K. Rollet, E. E. M. Moodie et al., "Insulin resistance is associated with progression to hepatic fbrosis in a cohort of HIV/hepatitis C virus-coinfected patients", AIDS, vol. 26, no. 14, pp. 1789-1794, 2012.
63. J. Collazos, J. A. Cartón, and V. Asensi, "Gender diferences in liver fbrosis and hepatitis C virus-related parameters in patients coinfected with human immunodefficiency virus", Current HIV Research, vol. 9, no. 5, pp. 339-345, 2011.
64. L. M. Villar, J. A. Del Campo, I. Ranchal, E. Lampe, and M. Romero-Gomez, "Association between vitamin D and hepatitis C virus infection: a meta-analysis", World Journal of Gastroenterology, vol. 19, no. 35, pp. 5917-5924, 2013.
65. S. Abramovitch, L. Dahan-Bachar, E. Sharvit et al., "Vitamin D inhibits proliferation and profbrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fbrosis in rats", Gut, vol. 60, no. 12, pp. 1728-1737, 2011.
66. L. Milazzo, C. Mazzali, G. Bestetti et al., "Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population", Current HIV Research, vol. 9, no. 3, pp. 186-193, 2011.
67. H. Farnik, J. Bojunga, A. Berger et al., "Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients", Hepatology, vol. 58, no. 4, pp. 1270-1276, 2013.
68. M. Mandorfer, T. Reiberger, B. A. Payer et al., "Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients", AIDS, vol. 27, no. 2, pp. 227-232, 2013.
69. A. D. Branch, M. Kang, K. Hollabaugh, C. M. Wyatt, R. T. Chung, and M. J. Glesby, "In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use", The American Journal of Clinical Nutrition, vol. 98, no. 2, pp. 423-429, 2013.
70. S. Abu-Mouch, Z. Fireman, J. Jarchovsky, A.-R. Zeina, and N. Assy, "Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-näive patients", World Journal of Gastroenterology, vol. 17, no. 47, pp. 5184-5190, 2011.
71. M. Gal-Tanamy, L. Bachmetov, A. Ravid et al., "Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes", Hepatology, vol. 54, no. 5, pp. 1570-1579, 2011.
72. Y. Kondo, T. Kato, O. Kimura et al., "1 (OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patientscase controlled trial", PLoS ONE, vol. 8, no. 5, Article ID e63672, 2013.
73. C. J. Murray, K. F. Ortblad, C. Guinovart et al., "Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013", The Lancet, vol. 384, no. 9947, pp. 1005-1070, 2013.
74. S. D. Lawn, S. T. Butera, and T. M. Shinnick, "Tuberculosis unleashed: the impact of human immunodefficiency virus infection on the host granulomatous response to Mycobacterium tuberculosis" Microbes and Infection, vol. 4, no. 6, pp. 635-646, 2002.
75. K. B. Gibney, L. MacGregor, K. Leder et al., "Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa", Clinical Infectious Diseases, vol. 46, no. 3, pp. 443-446, 2008.
76. J. Rathored, S. K. Sharma, B. Singh et al., "Risk and outcome of multidrug-resistant tuberculosis: vitamin D receptor polymorphisms and serum 25 (OH) D", The International Journal of Tuberculosis and Lung Disease, vol. 16, no. 11, pp. 1522-1528, 2012.
77. A. R. Martineau, P. M. Timms, G. H. Bothamley et al., "Highdose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial", The Lancet, vol. 377, no. 9761, pp. 242-250, 2011.
78. C. R. Sudfield, E. L. Giovannucci, S. Isanaka et al., "Vitamin D status and incidence of pulmonary tuberculosis, opportunistic infections, and wasting among HIV-infected tanzanian adults initiating antiretroviral therapy", The Journal of Infectious Diseases, vol. 207, no. 3, pp. 378-385, 2013.
79. K. E. Nnoaham and A. Clarke, "Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis", International Journal of Epidemiology, vol. 37, no. 1, pp. 113-119, 2008.
80. M. A. French, M. S. King, J. M. Tschampa, B. A. Da Silva, and A. L. Landay, "Serum immune activation markers are persistently increased in patients with HIV infection afer 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T Cells", Journal of Infectious Diseases, vol. 200, no. 8, pp. 1212-1215, 2009.
81. S. R. Ostrowski, T. L. Katzenstein, B. K. Pedersen, J. Gerstof, and H. Ullum, "Residual viraemia in HIV-1-infected patients with plasma viral load = 20 copies/ml is associated with increased blood levels of soluble immune activation markers", Scandinavian Journal of Immunology, vol. 68, no. 6, pp. 652-660, 2008.
82. D. A. Duprez, J. Neuhaus, L. H. Kuller et al., "Infammation, coagulation and cardiovascular disease in HIV-infected individuals", PLoS ONE, vol. 7, no. 9, Article ID e44454, 2012.
83. A. De Luca, K. De Gaetano Donati, M. Colafigli et al., "The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study", BMC Infectious Diseases, vol. 13, no. 1, article 414, 2013.
84. Á. H. Borges, M. J. Silverberg, D. Wentworth et al., "Predicting risk of cancer during HIV infection: the role of infammatory and coagulation biomarkers", AIDS, vol. 27, no. 9, pp. 1433-1441, 2013.
85. A. Biron, C. Bobin-Dubigeon, C. Volteau et al., "Metabolic syndrome in french HIV-infected patients: prevalence and predictive factors afer 3 years of antiretroviral therapy", AIDS Research and Human Retroviruses, vol. 28, no. 12, pp. 1672-1678, 2012.
86. A. C. Hearps, G. E. Martin, R. Rajasuriar, and S. M. Crowe, "Infammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing", Current HIV/AIDS Reports, vol. 11, no. 1, pp. 20-34, 2014.
87. K. W. Colston, L. C. Lowe, J. L. Mansi, and M. J. Campbell, "Vitamin D status and breast cancer risk", Anticancer Research, vol. 26, no. 4, pp. 2573-2580, 2006.
88. T. Mizoue, Y. Kimura, K. Toyomura et al., "Calcium, dairy foods, vitamin D, and colorectal cancer risk: the fukuoka colorectal cancer study", Cancer Epidemiology Biomarkers & Prevention, vol. 17, no. 10, pp. 2800-2807, 2008.
89. A. Bakhru, J. B. Mallinger, R. J. Buckanovich, and J. J. Griggs, "Casting light on 25-hydroxyvitamin D defficiency in ovarian cancer: a study from the NHANES", Gynecologic Oncology, vol. 119, no. 2, pp. 314-318, 2010.
90. G. G. Schwartz, "Vitamin D and intervention trials in prostate cancer: from theory to therapy", Annals of Epidemiology, vol. 19, no. 2, pp. 96-102, 2009.
91. K. M. Erlandson, I. Gudza, S. Fiorillo et al., "Relationship of vitamin D insuficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe", International Journal of Infectious Diseases, vol. 24, pp. 6-10, 2014.
92. EACSEACSgpamon-iciHOA, 2014, http://www.eacsociety.org/Portals/0/Guidelines Online 131014.pdf.
93. G. A. McComsey, P. Tebas, E. Shane et al., "Bone disease in HIV infection: a practical review and recommendations for HIV care providers", Clinical Infectious Diseases, vol. 51, no. 8, pp. 937-946, 2010.
94. M. Chung, J. Lee, T. Terasawa, J. Lau, and T. A. Trikalinos, "Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U. S. preventive services task force", Annals of Internal Medicine, vol. 155, no. 12, pp. 827-838, 2011.
95. M. F. Holick, "Medical progress: vitamin D defficiency", The New England Journal of Medicine, vol. 357, no. 3, pp. 266-281, 2007.
96. V. Groleau, R. A. Herold, J. I. Schall et al., "Blood lead concentration is not altered by high-dose vitamin D supplementation in children and young adults with HIV", Journal of Pediatric Gastroenterology & Nutrition, vol. 56, no. 3, pp. 311-315, 2013.
97. A. S. Ettinger, H. Lamadrid-Figueroa, M. M. Téllez-Rojo et al., "Efect of calcium supplementation on blood lead levels in pregnancy: a randomized placebo-controlled trial", Environmental Health Perspectives, vol. 117, no. 1, pp. 26-31, 2009.
98. C. T. Longenecker, C. O. Hileman, T. L. Carman et al., "Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial", Antiviral Terapy, vol. 17, no. 4, pp. 613-621, 2012.
99. V. Giacomet, A. Vigano, V. Manfredini et al., "Cholecalciferol supplementation in HIV-infected youth with vitamin d insufficiency: effects on vitamin d status and t-cell phenotype: a randomized controlled trial", HIV Clinical Trials, vol. 14, no. 2, pp. 51-60, 2013.